By Valorisation we mean translating research results into concrete social and economic value for society. This way, we ensure that innovative cancer treatments do not remain on paper but become accessible to patients and society. 

For Oncode Institute it means the translation of our research into clinical benefit for cancer patients. To optimize our valorisation efforts, we select the most appropriate modality for each opportunity. We use a model of six channels of valorisation and have dedicated funds for IP protection, technology development, clinical proof-of-concept and seed funding.

From research to impact in clinical practice

A key differentiator of Oncode Institute is its focus on valorisation: turning scientific discoveries into concrete patient applications. Together with the Oncode Investigators, our valorisation experts work to translate scientific knowledge into initial applications, products, and potential therapies. During the process, they may commit additional resources to protecting intellectual property (IP Fund), technical validation (Technology Development Fund), initial clinical trials (Clinical Proof-of-Concept Fund), or help to establish a company that can continue development (Oncology Bridge Fund). We involve all the parties necessary to develop an innovation, including initiation of public-private partnerships. In this way, we ensure that innovative cancer treatments do not just remain on paper but become accessible to patients and society.